SEARCH

SEARCH BY CITATION

References

  • 1
    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289300.
  • 2
    Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 47784.
  • 3
    Gurwitz JH, Everitt DE, Monane M et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996; 51: M749.
  • 4
    Whelton A, White WB, Bello AE, Puma JA, Fort JG. SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 95963.
  • 5
    Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2006; 5: 8394.
  • 6
    Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 4906.
  • 7
    Conlin PR, Moore TJ, Swartz SL et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000; 36: 4615.
  • 8
    Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine and enalapril. Am J Hypertens 2000; 13: 11617.
  • 9
    VIOXX® (rofecoxib tablets and oral suspension) [package insert]. Merck & Co, Inc. Whitehouse Station, NJ 08889; August 2004.http://www.merck.com/product/usa/pi_circulars/v/vioxx/vioxx_pi.pdf (accessed 03 Feb 2010).
  • 10
    MacDonald TM, Littlejohn TW, Richard D, Lheritier K, Krammer G, Reginster J-Y. Improved blood pressure control but similar efficacy with lumiracoxib 100 mg od compared to ibuprofen 600 mg tid in hypertensive patients with osteoarthritis: randomized controlled trial [Abstract SAT0239]. Ann Rheum Dis 2007; 66(Suppl. II): 502.
  • 11
    MacDonald TM, Reginster J-Y, Littlejohn TW et al. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens 2008; 26: 1695702.
  • 12
    Brufen 600 mg Tablets [summary of product characteristics]. Abbott Laboratories Limited, Maidenhead, Berkshire, SL6 4XE, UK; Jan 2010. http://emc.medicines.org.uk/medicine/10850/SPC/Brufen+600+mg+Tablets (accessed 03 Feb 2010).
  • 13
    Lehmann R, Brzosko M, Kopsa P et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005; 21: 51726.
  • 14
    Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 2005; 27: 6477.
  • 15
    Martin-Mola E, Munoz-Gomez J, Sánchez-Burson J et al. Celecoxib is as effective as ibuprofen in treating pain associated with osteoarthritis of the knee (abstract). Ann Rheum Dis 2005; 64(Suppl. III): 495.
  • 16
    Fogari R, Zoppi A, Carretta R, Veglio F, Salvetti A. Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. J Hypertens 2002; 20: 100714.
  • 17
    Palmgren E, Widgren B, Aurell M, Herlitz H. Increased renal vascular sensitivity to angiotensin II in hypertension is due to decreased response to prostaglandins. J Hypertens 2003; 21: 96976.
  • 18
    Fricker AF, Nussberger J, Meilenbrock S, Brunner HR, Burnier M. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int 1998; 54: 208997.
  • 19
    Juhlin T, Erhardt LR, Ottosson H, Jönsson BA, Höglund P. Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition. Eur J Heart Fail 2007; 9: 1916.
  • 20
    Pavličević I, Kuzmanić M, Rumboldt M, Rumboldt Z. Interaction between antihypertensive and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008; 15: e37282. Epub 2008 October 24.
  • 21
    Houston MC, Weir M, Gray J et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155: 104954.
  • 22
    Klassen D, Goodfriend TL, Schuna AA, Young DY, Peterson CA. Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. J Clin Pharmacol 1993; 33: 9718.
  • 23
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. U.S. Department of Health and Human Services. NIH Publication No. 04-5230; August 2004. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf (accessed 03 Feb 2010).
  • 24
    Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62: 44362.
  • 25
    Whitehead A, Simmonds M, Mellein B, Friede T, Gitton X, Sallstig P. Blood pressure profile of lumiracoxib is similar to placebo in arthritis patients [Abstract P309]. Osteoarthritis Cartilage 2006; 14(Suppl. 2): S1689.
  • 26
    Chalmers JP, West MJ, Wing LM, Bune AJ, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens 1984; 6: 107793.
  • 27
    Singh G, Miller JD, Huse DM, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the third national health and nutrition examination survey. Am J Manag Care 2002; 8: S38391.
  • 28
    Schnitzer TJ, Burmester GR, Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 66574.
  • 29
    Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 15208.